Measure tumor response
to assess changes in genomic alterations after treatment initiation.1,2

References

The only tissue-free biopsy to measure treatment response.1

>50% reduction in ctDNA is associated with significantly longer
progression-free survival (PFS).1,2

See treatment response in as soon as
4 weeks with just a simple blood test.³

Reduce ambiguity between progression and pseudo-progression when using immunotherapy.1,2

Important Note: The Guardant360 Response test was developed, and its performance characteristics determined, by the Guardant Health Clinical Laboratory in Redwood City, CA, USA, which is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as qualified to perform high-complexity clinical testing. Guardant360 Response refers to Guardant360 Response Laboratory Developed Test (LDT). This test has not been cleared or approved by the US FDA.

*For patients with advanced solid tumor cancers, placed on immunotherapy. Testing must occur 4-10 weeks after therapy initiation.

Now covered by Medicare for all advanced solid tumors.*